Accel Research Sites participating in clinical trial for Regeneron

Create a Profile

First Name(Required)

Last Name(Required)

Location Preference(Required)

Phone*(Required)

Email Address*(Required)

Gender

Conditions*(Required)

Race / Ethnicity

Contact Preferences(Required)

I accept digital forms of communication(Required)

I confirm that (1) the name and contact information set forth above is my name and contact information or that I am submitting the form on behalf of an individual who has legally authorized me to submit this request; (2) the personal information I provide in this form may be used by Accel Research Sites, and its affiliates, partners, and medical professionals in connection with considering my potential participation in clinical research studies; (3) I am requesting that Accel Research Sites contact me using the information I have provided on Accel Research Sites’ website; and (4) I have read and understand Accel Research Sites’ Privacy Policy.

CAPTCHA

Hidden

UTM Source

Hidden

UTM Campaign

Comments

This field is for validation purposes and should be left unchanged.

Create a Profile

First Name(Required)

Last Name(Required)

Location Preference*(Required)

Phone*(Required)

Email Address*(Required)

Gender

Conditions of Interest*(Required)

Race / Ethnicity

Contact Preferences*(Required)

I accept digital forms of communication(Required)

CAPTCHA

Hidden

UTM Source

Hidden

UTM Campaign

Phone

This field is for validation purposes and should be left unchanged.

Get In Touch Mobile

Name(Required)

Last Name(Required)

Phone

Email(Required)

Reason for Contact(Required)

Enter additional message or questions(Required)

I accept digital forms of communication(Required)

I confirm that the name and contact information set forth above is my name and contact information or that I am submitting the form on behalf of an individual who has legally authorized me to submit this request; (2) the personal information I provide in this form may be used by Accel Research Sites, and its affiliates, partners, and medical professionals in connection with considering my potential participation in clinical research studies; (3) I am requesting that Accel Research Sites contact me using the information I have provided on Accel Research Sites’ website; and (4) I have read and understand Accel Research Sites’ Privacy Policy.

CAPTCHA

Name

This field is for validation purposes and should be left unchanged.

FIND A TRIAL NEAR YOU

-- or --

Select City No location found for this Location

FIND A TRIAL NEAR YOU

-- or --

Select City No location found for this Location

Back

Date Published: 10/06/2020

Accel Research Sites participating in clinical trial for Regeneron

After he tested positive for COVID-19, President Trump made headlines when he received the experimental antibody cocktail REGN-COV2, made by Regeneron, under a compassionate use request.

The drug is now being evaluated for the treatment and prevention of COVID-19 in clinical trials. Accel Research Sites is proud to serve as a trial location in Eatonton, Georgia, through Lake Country Medical Group and principal investigator Dr. Nicolas Chronos.

“Treatments and vaccines for COVID-19 are in the news and on people’s minds,” said Matt Maxwell, CEO of Accel Research Sites. “At Accel Research Sites, we’ve always been proud to be on the leading edge of treatment options through clinical trials, and that’s more visible now than ever. It’s exciting to be part of testing Regeneron’s therapy.”

REGN-COV2 is a combination of two monoclonal antibodies and was designed to block infectivity of SARS-CoV-2, the virus that causes COVID-19. The drug is being studied for treatment and prevention of the disease. It is currently in Phase 3 clinical trials, enrolling both hospitalized and non-hospitalized participants, as well as those at risk of infection through close household exposure to a COVID-19 patient.

Regeneron previously released positive data for the treatment, stating that it reduced viral load and time to alleviate symptoms in non-hospitalized COVID-19 patients. It also showed positive trends in reducing medical visits, and the dosages were well-tolerated.

Accel Research Sites is currently enrolling participants in this clinical trial. Those interested should visit accelresearchsites.com or call (386) 785-2400 to see if they qualify.

Accel Research Sites provides novel treatment options in all major therapeutic areas. It has more than 30 locations.

Back

Articles